Pharmacokinetics, Safety and Tolerability of Tamsulosin Hydrochloride in Children With Voiding Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate pharmacokinetics, safety, and tolerability of tamsulosin hydrochloride in children with voiding disorders

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder

NCT00796614

Bladder, Neurogenic

COMPLETED PHASE2/PHASE3

PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder

NCT00340704

Bladder, Neurogenic

COMPLETED PHASE2

A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

NCT01565694

Neurogenic Detrusor Overactivity

COMPLETED PHASE3

Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry)

NCT06465576

Urinary Incontinence in Children

RECRUITING PHASE4

Prospective Trial Comparing Oxybutynin and Tamsulosin for Stent Pain in the Pediatric Population

NCT02483793

Disorder of Urinary Stent

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urination Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Flomax® Flomax® Flomax® Flomax®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Boys and girls with (or a history of) voiding disorders
* Age: 5 to 15 years
* Body weight and height ≥ 5 % and ≤95 % of normal using nomograms
* Signed and dated written informed consent by the parent or guardian and, where appropriate, informed assent by the child, prior to admission into the study in accordance with good clinical practice (GCP) and the local legislation, has been obtained

Exclusion Criteria

* Clinically significant abnormalities found at, or before randomization at Visit 2 \[i.e., abnormal: vital signs (e.g., hypotension), ECGs, as well as significant findings during the physical examination\], as determined by the investigator
* Clinically relevant conditions including, but not limited to, the following: gastrointestinal, cardiovascular (e.g., subjects that fall above the 90th percentile according to the blood pressure nomogram in the ISF), hepatic, renal, hematologic, metabolic (including diabetes mellitus), immunological, hormonal disorders, respiratory disease or cancer
* Subjects who had surgery within the last 30 days
* Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
* Subjects that have a neurological impairment or psychiatric disorder that prevents their comprehension of consent and their ability to comply with the protocol
* History of relevant orthostatic hypotension, fainting spells or blackouts. Postdural symptoms occurring (e.g., lightheadedness, dizziness, and fainting) with or without a change in blood pressure and / or pulse rate within 6 weeks of Visit 2
* Relevant acute infections, especially with regards to urinary tract infections or active genitourinary infection
* History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
* Subjects with known hypersensitivity to FLOMAX® (tamsulosin hydrochloride) or other alpha-blockers
* Use of medications classified as cytochrome P450 3A4 (CYP3A4) inhibitors and inducers within 10 days prior to administration of trial drug
* Intake of drugs with a long half-life (\> 24 hours) within less than 10 half-lives of the respective drug prior to administration
* Participation in another trial with an investigational drug within 1 month prior to administration or during the trial
* Inability to comply with dietary regimen of study center
* Pregnancy or subjects that are breast feeding
* All subjects parents and guardians in the investigator's opinion who cannot understand the terms of the informed consent form and subject information

Minimum Eligible Age

5 Years

Maximum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No